Progressive arm and leg stiffness in a patient with chronic renal impairment

Nature Clinical Practice Rheumatology

Volumn 4, Issue 10, 2008, Pages 557-562

  Shin, Kichul ^a,b   Granter, Scott R ^a,b   Coblyn, Jonathan S ^a,b   Gupta, Samardeep ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; C REACTIVE PROTEIN; CREATININE; FERRITIN; IMATINIB;

ADULT; ARTICLE; CASE REPORT; CELL PROLIFERATION; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEPHROGENIC FIBROSING DERMOPATHY; PHYSIOTHERAPY; PRIORITY JOURNAL; RIGIDITY; SKIN BIOPSY; SKIN FIBROSIS; SKIN TIGHTNESS; WALKING DIFFICULTY;

CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM DTPA; HUMANS; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; SCLERODERMA, SYSTEMIC; SYNDROME;

EID: 53849135882     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0883     Document Type: Article

References (23)

1. Cowper SE et al. (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patipnts. Lancet 356: 1000-1001
2. Galan A et al. (2006) Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 18: 614-617
3. Swaminathan S et al. (2006) Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 145: 234-235
4. Grobner T (2006) Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21: 1104-1108
5. Deo A et al. (2007) Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2: 264-267
6. Todd DJ et al. (2007) Cutaneous changes of nephrogenic systemic fibrosis: Predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 56: 3433-3441
7. Marckmann P et al. (2006) Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17: 2359-2362
8. High WA et al. (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 21-26
9. Sadowski EA et al. (2007) Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology 243: 148-157
10. Broome DR et al. (2007) Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. AJR Am J Roentgenol 188: 586-592
11. Mendoza FA et al. (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35: 238-249
12. Cowper SE (2003) Nephrogenic fibrosing dermopathy: The first 6 years. Curr Opin Rheumatol 15: 785-790
13. Moschella SL et al. (2004) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med 351: 2219-2227
14. Cowper SE et al. (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23: 383-393
15. Introcaso CE et al. (2007) Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: A case series of nine patients and review of the literature. Int J Dermatol 46: 447-452
16. Scheinfeld N (2006) Nephrogenic fibrosing dermopathy: A comprehensive review for the dermatologist. Am J Clin Dermatol 7: 237-247
17. Jimenez SA et al. (2004) Dialysis-associated systemic. fibrosis (nephrogenic fibrosing dermopathy): Study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50: 2660-2666
18. Cowper SE (2005) Nephrogenic systemic fibrosis: The nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 46: 763-765
19. Gilliet M et al. (2005) Successful treatment of three cases or nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 152: 531-536
20. Distler JH et al. (2007) Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56: 311-322
21. Kay J (2007) Imatinib mesylatte treatment improves skin changes of nephrogenic systemic fibrosis [abstact #32]. Arthritis Rheum 56 (Suppl): S64-S65. Presented at the ACR/ARHP Annual Scientific Meeting: 2007 November 6-11, Boston, MA
22. Thomsen HS (2007) ESUR guideline: Gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 17: 2692-2696
23. Food and Drug Administration Public Health Advisory (online 8 June 2006; updated 23 May 2007) Information on Gadolinium-Containing Contrast Agents [http://www.fda.gov/cder/drug/infopage/gcca/default.htm] (accessed 14 July 2008)